{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:17:38Z","timestamp":1773296258707,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":823,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1124\/jpet.122.001174","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T18:05:28Z","timestamp":1661969128000},"page":"103-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen\/Hypoxia Rat Model of Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"383","author":[{"given":"Michel R.","family":"Corboz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Plaunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir S.","family":"Malinin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhili","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Gauani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cipolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter R.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard W.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001174_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.cardiores.2003.08.017","article-title":"Induction of myocardial biglycan in heart failure in rats--an extracellular matrix component targeted by AT(1) receptor antagonism","volume":"60","author":"Ahmed","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1124\/jpet.122.001174_bib2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1080\/08958370802207318","article-title":"Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals","volume":"20","author":"Alexander","year":"2008","journal-title":"Inhal Toxicol"},{"key":"10.1124\/jpet.122.001174_bib3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1165\/rcmb.2005-0289OC","article-title":"Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts","volume":"34","author":"Ali","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1124\/jpet.122.001174_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.prostaglandins.2013.07.001","article-title":"A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor","volume":"107","author":"Benyahia","year":"2013","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1124\/jpet.122.001174_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejphar.2017.05.052","article-title":"RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-hypoxia-induced pulmonary arterial hypertension in rats","volume":"810","author":"Bhat","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.122.001174_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00592-2020","article-title":"Characterization of cough evoked by inhaled treprostinil and treprostinil palmitil","volume":"7","author":"Chapman","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1124\/jpet.122.001174_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102002","article-title":"An overview of the biology of a long-acting inhaled treprostinil prodrug","volume":"65","author":"Chapman","year":"2020","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1124\/jpet.122.001174_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2020.101983","article-title":"Treprostinil palmitil, an inhaled long-acting pulmonary vasodilator, does not show tachyphylaxis with daily dosing in rats","volume":"66","author":"Chapman","year":"2021","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1124\/jpet.122.001174_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pupt.2018.02.002","article-title":"Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil","volume":"49","author":"Chapman","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1124\/jpet.122.001174_bib10","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1111\/bph.14472","article-title":"Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling","volume":"175","author":"Chaudhary","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.122.001174_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.prostaglandins.2015.04.007","article-title":"The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: role of membrane versus nuclear receptors","volume":"120","author":"Clapp","year":"2015","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1124\/jpet.122.001174_bib12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/jpet.117.242099","article-title":"Preclinical pharmacology and pharmacokinetics of inhaled hexadecyl-treprostinil (C16TR), a pulmonary vasodilator prodrug","volume":"363","author":"Corboz","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001174_bib13","first-page":"A3678","article-title":"Pulmonary vasodilator activity of inhaled treprostinil palmitil, inhaled treprostinil, intravenous treprostinil and oral selexipag in hypoxia challenged rats (Abstract)","volume":"203","author":"Corboz","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/jpet.122.001174_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174484","article-title":"Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension","volume":"916","author":"Corboz","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.122.001174_bib15","article-title":"Prostanoid receptor subtypes involved in treprostinil-mediated vasodilation of rat pulmonary arteries and in treprostinil-mediated inhibition of collagen gene expression of human lung fibroblasts","volume":"152","author":"Corboz","year":"2021","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1124\/jpet.122.001174_bib16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1183\/09031936.00204813","article-title":"SuHx rat model: partly reversible pulmonary hypertension and progressive intima obstruction","volume":"44","author":"de Raaf","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1124\/jpet.122.001174_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/730683","article-title":"Sca-1+ cells from fetal heart with high aldehyde dehydrogenase activity exhibit enhanced gene expression for self-renewal, proliferation, and survival","volume":"2015","author":"Dey","year":"2015","journal-title":"Oxid Med Cell Longev"},{"key":"10.1124\/jpet.122.001174_bib18","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1111\/febs.12235","article-title":"Lumican is increased in experimental and clinical heart failure, and its production by cardiac fibroblasts is induced by mechanical and proinflammatory stimuli","volume":"280","author":"Engebretsen","year":"2013","journal-title":"FEBS J"},{"key":"10.1124\/jpet.122.001174_bib19","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.bbrc.2007.06.135","article-title":"IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues","volume":"360","author":"Falcetti","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.122.001174_bib20","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/bjp.2008.214","article-title":"Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype","volume":"154","author":"Foudi","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.122.001174_bib21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/pr.111.005587","article-title":"The pharmacological treatment of pulmonary arterial hypertension","volume":"64","author":"Frumkin","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.122.001174_bib22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/hrt.14.3.413","article-title":"Ventricular weight in cardiac hypertrophy","volume":"14","author":"Fulton","year":"1952","journal-title":"Br Heart J"},{"key":"10.1124\/jpet.122.001174_bib23","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/cphy.c140048","article-title":"The dystrophin complex: structure, function, and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr Physiol"},{"key":"10.1124\/jpet.122.001174_bib24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1124\/jpet.116.239665","article-title":"Selexipag active metabolite ACT-333679 displays strong anticontractile and antiremodeling effects but low \u03b2-arrestin recruitment and desensitization potential","volume":"362","author":"Gatfield","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001174_bib25","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/j.1365-2559.1985.tb02811.x","article-title":"The assessment of cardiac hypertrophy at autopsy","volume":"9","author":"Hangartner","year":"1985","journal-title":"Histopathology"},{"key":"10.1124\/jpet.122.001174_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240692","article-title":"The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416\/hypoxia-induced pulmonary arterial hypertension in rats","volume":"15","author":"Honda","year":"2020","journal-title":"PLoS One"},{"key":"10.1124\/jpet.122.001174_bib27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/00498254.2017.1294277","article-title":"Pharmacokinetics of the selective prostacyclin receptor agonist selexipag in rats, dogs and monkeys","volume":"48","author":"Ichikawa","year":"2018","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.122.001174_bib28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1165\/rcmb.2014-0488OC","article-title":"Marked strain-specific differences in the SU5416 rat model of severe pulmonary arterial hypertension","volume":"54","author":"Jiang","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1124\/jpet.122.001174_bib29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1165\/rcmb.2002-0243OC","article-title":"Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation","volume":"29","author":"Kolodsick","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1124\/jpet.122.001174_bib30","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s40262-016-0409-0","article-title":"A comprehensive review of treprostinil pharmacokinetics via four routes of administration","volume":"55","author":"Kumar","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/jpet.122.001174_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205195","article-title":"Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells","volume":"13","author":"Lambers","year":"2018","journal-title":"PLoS One"},{"key":"10.1124\/jpet.122.001174_bib32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1055\/s-0044-100374","article-title":"Inhaled treprostinil-prodrug lipid nanoparticle formulations provide long-acting pulmonary vasodilation","volume":"68","author":"Leifer","year":"2018","journal-title":"Drug Res (Stuttg)"},{"key":"10.1124\/jpet.122.001174_bib33","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1161\/01.CIR.70.3.425","article-title":"Pulsed Doppler echocardiographic determination of stroke volume and cardiac output: clinical validation of two new methods using the apical window","volume":"70","author":"Lewis","year":"1984","journal-title":"Circulation"},{"key":"10.1124\/jpet.122.001174_bib34","doi-asserted-by":"crossref","first-page":"H1375","DOI":"10.1152\/ajpheart.00053.2015","article-title":"The role of sirtuins in cardiac disease","volume":"309","author":"Matsushima","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/jpet.122.001174_bib55","first-page":"A4612","article-title":"Binding affinity of treprostinil to rat recombinant prostanoid receptors IP and EP2","volume":"205","author":"Nguyen","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/jpet.122.001174_bib35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0014-5793(00)02156-6","article-title":"Agonist-induced long-term desensitization of the human prostacyclin receptor","volume":"484","author":"Nilius","year":"2000","journal-title":"FEBS Lett"},{"key":"10.1124\/jpet.122.001174_bib36","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.bbadis.2016.10.004","article-title":"Targeting acetaldehyde dehydrogenase 2 (ALDH2) in heart failure-recent insights and perspectives","volume":"1863","author":"Pang","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1124\/jpet.122.001174_bib37","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.3390\/ijms19082372","article-title":"Prostanoid EP2 receptors are up-regulated in human pulmonary arterial hypertension: a key anti-proliferative target for treprostinil in smooth muscle cells","volume":"19","author":"Patel","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.122.001174_bib38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/cvr\/cvv096","article-title":"Peptidyl-prolyl isomerases: a full cast of critical actors in cardiovascular diseases","volume":"106","author":"Perrucci","year":"2015","journal-title":"Cardiovasc Res"},{"key":"10.1124\/jpet.122.001174_bib39","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/ijms22020548","article-title":"Development and characterization of treprostinil palmitil inhalation aerosol for the investigational treatment of pulmonary arterial hypertension","volume":"22","author":"Plaunt","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.122.001174_bib40","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1152\/japplphysiol.00083.2005","article-title":"Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation","volume":"99","author":"Sandifer","year":"2005","journal-title":"J Appl Physiol"},{"key":"10.1124\/jpet.122.001174_bib41","doi-asserted-by":"crossref","first-page":"L1013","DOI":"10.1152\/ajplung.00217.2009","article-title":"Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure","volume":"297","author":"Stenmark","year":"2009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1124\/jpet.122.001174_bib42","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1096\/fj.00-0343com","article-title":"Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension","volume":"15","author":"Taraseviciene-Stewart","year":"2001","journal-title":"FASEB J"},{"key":"10.1124\/jpet.122.001174_bib43","doi-asserted-by":"crossref","first-page":"H243","DOI":"10.1152\/ajpheart.00728.2013","article-title":"Temporal hemodynamic and histological progression in Sugen5416\/hypoxia\/normoxia-exposed pulmonary arterial hypertensive rats","volume":"306","author":"Toba","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/jpet.122.001174_bib44","doi-asserted-by":"crossref","first-page":"L401","DOI":"10.1152\/ajplung.00114.2010","article-title":"Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension","volume":"299","author":"Urboniene","year":"2010","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1124\/jpet.122.001174_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089621","article-title":"Pentosan polysulfate decreases myocardial expression of the extracellular matrix enzyme ADAMTS4 and improves cardiac function in vivo in rats subjected to pressure overload by aortic banding","volume":"9","author":"Vistnes","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/jpet.122.001174_bib46","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.bbrc.2012.03.124","article-title":"Serendipitous discovery of a novel protein signaling mechanism in heart failure","volume":"421","author":"Vitello","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.122.001174_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/phy2.184","article-title":"Progressive right ventricular functional and structural changes in a mouse model of pulmonary arterial hypertension","volume":"1","author":"Wang","year":"2013","journal-title":"Physiol Rep"},{"key":"10.1124\/jpet.122.001174_bib48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcp.2012.03.012","article-title":"Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist","volume":"84","author":"Whittle","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.122.001174_bib49","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/10408449309104076","article-title":"Toxicologic testing of inhaled pharmaceutical aerosols","volume":"23","author":"Wolff","year":"1993","journal-title":"Crit Rev Toxicol"},{"key":"10.1124\/jpet.122.001174_bib50","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1378\/chest.15-1029","article-title":"Prostanoids in asthma and COPD: actions, dysregulation, and therapeutic opportunities","volume":"148","author":"Zaslona","year":"2015","journal-title":"Chest"},{"key":"10.1124\/jpet.122.001174_bib51","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3389\/fphys.2017.01089","article-title":"Proton-translocating nicotinamide nucleotide transhydrogenase: a structural perspective","volume":"8","author":"Zhang","year":"2017","journal-title":"Front Physiol"},{"key":"10.1124\/jpet.122.001174_bib52","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comp Methods Prog Biomed"},{"key":"10.1124\/jpet.122.001174_bib53","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019841987","article-title":"Echocardiographic assessment of right ventricular function in experimental pulmonary hypertension","volume":"9","author":"Zhu","year":"2019","journal-title":"Pulm Circ"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652400329X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652400329X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:26:51Z","timestamp":1739971611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652400329X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S002235652400329X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001174","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen\/Hypoxia Rat Model of Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The Author(s)","name":"copyright","label":"Copyright"}]}}